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Introduction: The epidermal growth factor receptor (EGFR) inhibi-
tor erlotinib is much less effective in non–small-cell lung cancer 
(NSCLC) tumors with wild-type EGFR, than in tumors with acti-
vating EGFR mutations. Autophagy is a tightly regulated lysosomal 
self-digestion process, which may alternatively promote cell survival 
or type II cell death. This study assessed the role of autophagy in 
erlotinib-mediated cytotoxicity.
Methods: We used wild-type EGFR erlotinib-sensitive and erlo-
tinib-resistant NSCLC cell lines to determine whether inhibiting 
autophagy by a therapeutic agent potentiated the antitumor activity 
of erlotinib in vitro and in vivo.
Results: Erlotinib at a clinically relevant concentration (2 μM) 
induced autophagy in NSCLC cells with wild-type EGFR, and the 
degree of induction was greater in cells that were resistant than 
sensitive, suggesting that autophagy is cytoprotective. This was 
confirmed by knockdown of the autophagy-related gene Atg-5, 
and by using the autophagy inhibitor chloroquine (CQ), both of 
which increased the cytotoxicity of erlotinib. The synergistic activ-
ity of CQ was not because of the potentiation of erlotinib’s effects 
on autophagy, cell-cycle arrest, and inhibition of both EGFR or 
downstream signaling of EGFR. Rather, CQ markedly activated 
apoptosis in the cells. The ability of CQ to potentiate the antitumor 
activity of erlotinib was also seen in mice bearing NSCLC tumor 
xenografts.
Conclusions: The ability to adapt to anti-EGFR therapy by trigger-
ing autophagy may be a key determinant for resistance to erlotinib in 
wild-type EGFR NSCLC. Inhibition of autophagy by CQ represents 
a novel strategy to broaden the spectrum of erlotinib efficacy in wild-
type EGFR NSCLC tumors.
Key Words: Autophagy inhibitors, Erlotinib, Epidermal growth fac-
tor receptor, Non–small-cell lung cancer.
(J Thorac Oncol. 2013;8: 693-702)
Erlotinib (Tarceva) is an orally bioavailable epidermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tor (TKI), which blocks signal transduction pathways impli-
cated in cell proliferation and survival.1,2 Erlotinib is currently 
approved for the treatment of chemorefractory non–small-cell 
lung cancer (NSCLC) and maintenance therapy after front-
line chemotherapy.3,4 It is most active in NSCLC tumors that 
carry activating EGFR mutations, with only modest antitu-
mor activity in NSCLC tumors that have wild-type EGFR.5,6 
The reasons for the innate resistance to erlotinib in wild-type 
EGFR NSCLC tumors have not been investigated in depth. 
Although many of these tumors have an activated EGFR path-
way, either such activation is not essential for cell survival and 
proliferation, or its inhibition rapidly triggers effective mecha-
nisms of cell adaptation.7
Autophagy is a process that allows cells to seques-
ter cytoplasmic contents, through the formation of double-
membrane vesicles (autophagosomes), and targets them for 
degradation, through their fusion with lysosomes, creating 
single-membrane autolysosomes.8 Emerging evidence indi-
cates that autophagy is a self-protective cellular mechanism, 
which provides energy through the degradation and recycling 
of cytoplasmic contents and promotes cell survival in response 
to a variety of stimuli.9 In addition to inducing apoptosis, anti-
neoplastic agents can also induce autophagy in cancer cells, 
and under certain conditions, autophagy and apoptosis seem 
to interact, either concurrently or sequentially, to positively or 
negatively determine cell fate.10,11
In our previous work, we along with others, have 
demonstrated that the mechanisms of erlotinib antitumor 
activity occur through inhibition of EGFR phosphorylation, 
inhibition of downstream signaling, blockade of cell-cycle 
progression at G
1
/S, and triggering of mitochondrial-
mediated intrinsic apoptotic cascades.12,13 However, little is 
known regarding autophagy induction by EGFR inhibitors 
and whether autophagy plays a role in cell death or acts as a 
survival mechanism. Here we demonstrate that erlotinib, at a 
clinically achievable concentration (2 μM), strongly induces 
autophagy in wild-type EGFR NSCLC cells. The degree 
of autophagy induction by erlotinib was greater in resistant 
cells than in sensitive cells, suggesting that its induction 
may constitute a mechanism of cytoprotection. An inhibitor 
of autophagy, chloroquine, potentiated the tumor inhibitory 
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effects of erlotinib in vitro and in vivo. The data presented 
provide a strong rationale for exploring combinations of 
erlotinib with autophagy inhibitors in the treatment of wild-
type EGFR NSCLC tumors.
MATERIALS AND METHODS
Chemicals and Antibodies
Erlotinib (OSI Pharmaceuticals, Melville, NY), was 
dissolved in dimethyl sulfoxide (DMSO); chloroquine was 
from Sigma-Aldrich (St. Louis, MO); hydroxychloroquine 
(HCQ) was from Sanofi US (Bridgewater, NJ). Polyclonal 
antibodies used were: EGFR, p-EGFR (Tyr1068), protein 
kinase 3 (AKT), p-AKT (Ser475), (Cell Signaling, Beverly, 
MA); microtubule-associated protein light chain 3 (LC3) 
(Novus Biologicals, La Jolla, CA); and monoclonal β-actin 
(Sigma-Aldrich).
Cell Lines
Human H322, H358, H460, and A549 NSCLC cell 
lines were from ATCC (Manassas, VA), and were maintained 
in RPMI-1640 medium, with 10% fetal bovine serum, peni-
cillin, and streptomycin at 37°C in a humidified atmosphere, 
with 5% carbon dioxide. All four cell lines have wild-type 
EGFR; H322 and H358 also have wild-type K-ras genes, 
whereas A549 and H460 have mutant K-ras (G12S and G61H, 
respectively).14
Cell Proliferation
Drug effects on cell proliferation were determined using 
two methods: cells were seeded in a 96-well plate (103 per 
well), allowed to attach overnight, and treated with various 
concentrations of erlotinib or CQ alone, or with combina-
tions of both agents, with a 1:5 molar ratio. In all experiments, 
medium containing 0.1% DMSO was used as a control. After 
7 days, cell viability was determined by the MTT assay. The 
combination index (CI), a measure of drug interaction (i.e., 
additivity, synergism), was assessed using CalcuSyn software 
(Biosoft, Ferguson, MO). Alternatively, cells were seeded in 
a 6-well plate (103 per well), allowed to attach overnight, and 
treated with 2 µM of erlotinib and 5 µM or 10 µM of CQ, 
alone or in combination. After 10 days, the cells were fixed 
and stained with crystal violet. Plates were scored for the 
number of visible colonies more than 2 mm.
Cell-Cycle Analysis
Cells were treated with 2 μM of erlotinib or 10 μM 
of CQ, alone or in combination, for 24 hours, and were then 
fixed with cold 75% ethanol overnight, and stained with 1 μg/
ml of propidium iodide and 5 μg/ml of RNase I for 3 hours. 
The cell-cycle distribution was assessed by FACScan (BD 
Biosciences, San Jose, CA) analysis.
Apoptosis Assay
Cells were treated with erlotinib or CQ, alone or in 
combination, for the indicated times, and apoptotic cells were 
determined using terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay. Apoptotic cells (sub-G
0
/G
1
) 
were measured by FACScan analysis, as described above.
Autophagy Assay
Cells were treated with 2 μΜ of erlotinib at 37° C for 72 
hours, and then incubated with 50 μM of monodansylcadav-
erine (MDC) at 37°C for 15 minutes. Autophagic cells were 
observed under a fluorescence microscope and the autophagic 
index was scored as percentage of MDC-labeled positive cells 
out of 200 cells.
Transmission Electron Microscopy
H322 and H460 cells were treated with 2 μM of erlo-
tinib for 72 hours, washed thrice with phosphate-buffered 
saline, and fixed with 0.5 ml of glutaraldehyde (2.5% in 0.1M 
cacodylate buffer, pH 7.4) at 4°C, overnight. After washing, 
cells were fixed in 1% OsO
4
 and embedded in polybed resin. 
The ultrathin sections were doubly stained with uranyl acetate 
and lead citrate and analyzed by transmission electron micros-
copy (JEOL; Peabody, MA).
Immunoblot Analysis
Cells were scraped from culture dishes, cell lysates were 
prepared, and immunoblot analysis was performed, as previ-
ously described.12
Down-Regulation of Atg-5 Gene 
Expression with Sirna
Atg5-siRNA and nonspecific control of siRNA (mock-
siRNA) were from Santa Cruz Biotechnology (Santa Cruz, 
CA). Cells at 75% confluence, were transiently transfected 
using Lipofectamine 2000 (Invitrogen, Grand Island, NY) 
with 50 pmol of siRNA/105 cells, according to the manufac-
turer’s instructions.
Animal Tumor Studies
Athymic nude mice (5–6 weeks of age; Harlan, South 
Easton, MA) were inoculated subcutaneously with 3 to 4 × 106 
H358 or H460 human NSCLC cells. After 7 days, when the 
tumor sizes averaged 5 × 5 mm, the mice were divided in 
groups of five and daily drug therapy was commenced. Drugs 
were administered by oral gavage as follows: vehicle con-
trol; erlotinib (30 mg/kg/day); HCQ (162 mg/kg/day); or the 
combination of HCQ + erlotinib. These doses were equiva-
lent to human doses of 150 mg and 800 mg per day for erlo-
tinib and HCQ, respectively. A total of 21 and 19 daily doses 
were administered to the H358 and H460 tumor-bearing mice, 
respectively. Mice were weighed weekly, and tumors were 
measured with calipers twice a week; tumor size was calcu-
lated as l × w2/2.
Statistical Analysis
Data are means ± standard error of mean (SEM). 
Comparisons were made with a t test and the difference was 
considered to be statistically significant if the p value was 
lesser than 0.05
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RESULTS
Erlotinib Induces Autophagy in Wild-Type  
EGFR Human NSCLC Cell Lines
Mitochondrial-mediated apoptosis plays a major role in 
cell death in erlotinib-sensitive cells.13,15 The role of autoph-
agy in the sensitivity and resistance of human NSCLC cells to 
erlotinib, however, has not been fully explored. In the present 
study, we measured the induction of autophagy after erlotinib 
in four previously identified human wild-type EGFR NSCLC 
cell lines; two of these (H322 and H358) are relatively sensi-
tive to erlotinib (IC
50
s of 1–2 μM), and two (H460 and A549) 
are relatively resistant (IC
50
s >10 μM).16 Cells were treated 
with erlotinib (2 μM for 72 hours), and were stained with 
MDC (50 μΜ), an autofluorescent base that accumulates in 
autophagic vacuoles.17 Cells with more than 10 puncta were 
FIGURE 1.  Erlotinib induces autophagy in human NSCLC cell lines. A, Cells were treated with 2 μM of erlotinib or with the 
same volume of medium containing 0.1% DMSO as a control for 72 hours. After treatment, cells were incubated with 50 μM 
of MDC for 15 minutes, and MDC-positive staining cells were analyzed with fluorescence microscopy. Autophagy percentage 
was assessed by counting MDC-positive cells out of 200 cells from each group; values are means ± SD of three experiments. 
*p value was less than 0.05 compared with control. B, Electron microscopy showed the ultrastructure of H322 and H460 cells 
after treatment with 2 μM of erlotinib for 72 hours. Arrows show autophagic vacuoles, including residual digested material and 
empty vacuoles. C, To assess the effect of knockdown of Atg-5 expression on erlotinib-induced cell death, cells were transiently 
transfected for 24 hours with Atg-5 siRNA, or with mock or no siRNA. After transfection, cells were treated with 4 μM of erlo-
tinib for an additional 24 hours. After treatment, the levels of Atg-5, LC3-I, and LC3-II were assessed by immunoblot analysis. 
D, Cells were transfected with Atg-5 or mock-siRNA and treated with 4 μM of erlotinib as in (C). After incubation for 10 days, 
the colonies were counted and were expressed relative to control. Data are means ± SD of three independent experiments, *p < 
0.05, **p < 0.01. MDC, monodansylcaverine; N, nucleus; NSCLC, non–small-cell lung cancer.
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assessed as MDC-positive. Erlotinib caused a significant 
increase in the number of MDC-positive cells, compared with 
control, in all four cell lines (Fig. 1A). Quantitative analysis 
showed the increase was greater (≤2.5-fold) in the resistant 
H460 and A549 cells, compared with the sensitive H322 and 
H358 cells (<1.5-fold).
We also used transmission electron microscopy to 
detect ultrastructural changes in NSCLC cells after treat-
ment with erlotinib. As shown in Figure 1B, H322 and 
H460 cells treated with erlotinib showed an increased for-
mation of vacuoles in the cytoplasm compared with con-
trols, consistent with the induction of autophagy. Some of 
the vacuoles resembled autophagosomes and contained 
remnants of degraded organelles. Moreover, more vacu-
oles were observed in erlotinib-resistant H460 cells than in 
H322 sensitive cells (Fig. 1B, arrowhead), suggesting that 
erlotinib-induced autophagy may represent a mechanism of 
cytoprotection and drug resistance.
Knockdown of Autophagy-Related Gene Atg-5 
by siRNA Enhances Erlotinib-Induced Cell Death
If erlotinib-induced autophagy is a cell-survival and 
drug-resistance mechanism, then disrupting the autophagic 
signaling pathways should enhance erlotinib-induced cyto-
toxicity in NSCLC cells. To test this hypothesis, we knocked 
down a key autophagy regulator, Atg-5, with siRNA in H460 
and A549 cells. We transiently transfected cells with Atg-5 
siRNA or nonspecific siRNA (mock-siRNA) using lipo-
fectamine 2000, as described in Materials and Methods. After 
a 24-hour transfection period, cells were treated with erlo-
tinib for an additional 24 hours and the levels of Atg-5 were 
determined by immunoblot. As shown in Figure 1C, Atg-5 
reduced substantially in both cell lines after siRNA transfec-
tions, as compared with controls. To determine whether Atg-5 
knockdown affected autophagy, we measured the conversion 
of the autophagy-associated protein LC3 from its cytoplasmic 
form (LC3-I) to autophagosome-associated form (LC3-II) 
by immunoblot analysis. As anticipated, erlotinib increased 
LC3-II levels in control and mock-transfected cells, consistent 
with the induction of autophagy (Fig. 1C).
LC3-II associates with both the inner and the outer 
membranes of the autophagosome, and is subsequently, 
degraded upon progression of the autophagosome to autoly-
sosomes; Atg-5 is required early in the process of autopha-
gosome formation at the vesicle nucleation stage.18,19 The 
erlotinib-induced increase in LC3-II levels was substantially 
blunted in Atg-5 siRNA-treated cells, indicating that the for-
mation of autophagosomes was effectively inhibited by Atg-5 
knockdown, and the cells were not able to induce autophagy 
(Fig. 1C). The blockade of autophagy induction by siRNA-
mediated down-regulation of Atg-5 had a consequential cell-
growth inhibitory effect, and notably, sensitized the cells to 
growth inhibition by erlotinib (Fig. 1D).
Combination with Chloroquine Synergistically 
Enhances Erlotinib-Induced Cytotoxicity
We next determined whether CQ, an antimalarial 
and antiarthritic drug that increases intralysosomal pH and 
impairs autophagic protein degradation, could also sensitize 
cells to erlotinib-induced cytotoxicity.20 Cells were plated 
at low density in 6-well plates and treated with erlotinib 
(2 μM), CQ (5 and 10 μΜ), or with combinations of erlotinib 
and CQ. After 10 days of drug treatment, the numbers of colo-
nies were quantified as described in Materials and Methods. 
As shown in Figure 2A and B, erlotinib caused a 68% and 53% 
reduction in cell colonies in H322 and H358 cells, respectively, 
whereas CQ had little effect (<18% decrease). However, the 
combination of erlotinib plus CQ caused an approximately 
80% to 95% reduction in colonies in H322 cells and an approx-
imately 70% to 93% decrease in H358 cells; the cytotoxic 
effects of the drug in combination was significantly different 
from that of either drug on its own. The toxicity-enhancing 
effect of CQ was more pronounced in the H460 and A549 
cells, whereas erlotinib alone caused only 12% and less than 
5% reductions, respectively. In these cells, the combination of 
erlotinib with 10 μM of CQ caused a nearly complete inhibi-
tion of H460 cell growth, and an approximately 70% reduction 
in A549 cells (p < 0.01). Thus, CQ increased the cytotoxicity of 
erlotinib in both erlotinib-resistant and -sensitive cells.
To assess whether the combination effects of erlotinib 
plus CQ were synergistic or addictive, we calculated the CI val-
ues, using the Chou–Talalay method (Fig. 2C and D).21 Cells 
were plated in 96-well plates and treated with erlotinib and CQ, 
alone or in combination; the drugs were combined at a fixed 
1:5 molar ratio. Cell numbers were determined after 7 days 
by an MTT assay. As previously shown, H322 and H358 cells 
were more sensitive to erlotinib (IC
50
 values of 1 and 1.8 μM, 
respectively) than H460 and A549 cells (IC
50
 values of 9.5 and 
18 μΜ, respectively) (Fig. 2C). CQ has little growth inhibitory 
effect in these cells (<30% at concentrations up to 20 μΜ). 
However, CQ caused a marked sensitization effect to erlotinib 
in all tested cell lines, with a greater effect (approximately 10- 
to 18-fold increase) seen in the resistant cells compared with 
the sensitive cells (approximately 3-fold increase). CI values in 
all combinations tested were less than 1.0, indicating that the 
drug interactions observed were highly synergistic (Fig. 2D).
Effect of Chloroquine on Erlotinib-Mediated 
Inhibition of EGFR Phosphorylation, 
Downstream Signaling, and Cell-Cycle Inhibition
After establishing that CQ potentiates erlotinib 
cytotoxicity, we next turned our focus to identifying 
potential mechanisms of action for the potentiating effect. 
We first evaluated the effect of the autophagy inhibitor on 
erlotinib-induced inhibition of EGFR phosphorylation and 
its downstream signaling. Cells were starved in serum-free 
medium for 24 hours, and then treated with 2 μM of erlotinib, 
10 μM of CQ alone, or with the combination of two agents 
for 24 hours, and were then stimulated with 30 ng/ml EGF 
for 10 minutes. Cell extracts were obtained for determination 
of total and phosphorylated EGFR, AKT, and extracellular 
signal related kinases (ERK). Immunoblot analysis showed 
that erlotinib strongly inhibits the phosphorylation of EGFR 
in all cell lines, whereas, CQ alone had no effect on the 
phosphorylation of this protein (Fig. 3). Erlotinib had an 
inhibitory effect on AKT phosphorylation in all cell lines, 
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and an inhibitory effect on ERK phosphorylation in three 
of the four cell lines. The effect of CQ alone on AKT and 
ERK phosphorylation was variable across the four cell lines, 
in some instances having no effect, but causing in others a 
modest inhibition. CQ did not enhance erlotinib-induced 
inhibition of EGFR, AKT, and ERK phosphorylation, 
suggesting that the cytotoxicity-sensitization effect is not 
because of further inhibition of the EGFR pathway.
In a previous work, we along with others demonstrated 
that erlotinib inhibits human NSCLC cell growth predominantly 
by suppressing cell-cycle events at the G
1
/S transition.12,22 To 
test whether the same effect occurs with CQ enhancement of 
erlotinib cytotoxicity, H322 and H460 cells were treated with 
erlotinib and CQ, alone or in combination for 72 hours, and cell-
cycle distribution was evaluated by FACScan analysis. Erlotinib 
alone induces G
1
-phase arrest, as expected, in H322, but not 
in H460 cells, whereas, CQ alone had no effect on cell-cycle 
progression (Fig. 4). Although the combination of erlotinib and 
CQ was associated with a decrease in cells at S and G
2
/M phase, 
it did not further increase the G
1
-arrest seen with erlotinib alone.
FIGURE 2.  Synergistic interactions of erlotinib and chloroquine in human NSCLC cell lines. A and B, NSCLC cells (103/well) 
were plated in 6-well plates overnight, and then treated with erlotinib (2 μM) and CQ (5 and 10 μM) alone, or in combination. 
After 10 days, plates were stained (A) and the number of colonies was quantified (B). Data are means ± SD of three independent 
experiments. *p < 0.05, and **p < 0.01 compared with erlotinib alone. C and D, Cells (103/well) were plated in 96-well plates 
overnight, and then treated with various concentrations of erlotinib or CQ alone, or with the combination of both agents with 
1:5 molar ratio. After 7 days cell numbers were determined by an MTT assay (C), and the CI (D) was determined using CalcuSyn 
software. Data points with a CI < 1, indicate a synergistic interaction between the drugs. CQ, chloroquine; NSCLC, non–small-
cell lung cancer; CI, combination index.
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Effect of Chloroquine on Erlotinib-Induced  
Autophagy
As shown above, induction of autophagy by erlotinib 
seems to act as a cell-survival and drug-resistance mechanism 
(Fig. 1). Under other conditions, autophagy has been shown 
to mediate type II cell death, and therefore, it is possible that 
the synergistic actions of CQ on NSCLC growth inhibition 
could be a consequence of the further modulation of erlotinib-
mediated induction of autophagy. To evaluate this possibility, 
we determined the effect of CQ on the conversion of the 
autophagy-associated protein LC3 from its cytoplasmic form 
(LC3-I) to autophagosome-associated form (LC3-II) by 
immunoblot analysis. As shown in Figure 5A, treatment with 
erlotinib alone led to increases in LC3-II levels, consistent 
FIGURE 3.  Cotreatment with CQ did 
not further impact erlotinib-induced sup-
pression of EGFR, AKT, and ERK1/2 phos-
phorylation in NSCLC cell lines. Cells were 
treated with 2 μM of erlotinib, 10 μM of 
CQ alone, or with a combination of both 
agents for 24 hours, and then were treated 
with EGF for 10 minutes (30 ng/ml). After 
treatment, cells were harvested and cell 
extracts were made for assay of total and 
phosphorylated EGFR, AKT, and ERK by 
immunoblot. β-Actin was used as sample 
loading control. NSCLC, non–small-cell 
lung cancer; EGFR, epidermal growth fac-
tor receptor; CQ, chloroquine.
FIGURE 4.  Effect of CQ on erlotinib-induced inhibi-
tion of cell-cycle progression and apoptosis in H322 
and H460 cells. H322 and H460 cells were treated 
with 2 μM of erlotinib or 10 μM of CQ, alone or in 
combination for 72 hours. Cells were harvested and 
stained with propidium iodide for assay of cell-cycle 
distribution by FACS analysis. Representative DNA 
histograms (A) and quantitative analysis of cell-cycle 
distribution (B) are shown. Combination with CQ 
did not alter erlotinib-induced G1-phase arrest, but 
dramatically increased the percentage of sub-G1 
apoptotic cells. CQ, chloroquine; FACS, fluores-
cence-activated cell sorting. 
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with the induction of autophagy as seen in Figure 1 (1.4-fold 
in H322 and H358 cells; approximately 2-fold in H460 and 
A549 cells). Treatment with CQ alone caused larger increases 
(3- to 5-fold) in the accumulation of LC3-II in all tested cell 
lines, which is likely because of the ability of CQ to block 
the autophagic process at a point subsequent to the formation 
of the autophagosome; this late-stage impairment inhibits 
the turnover of the autophagosomes and the degradation of 
autophagic proteins, including LC3-II.18 Of importance to this 
study was the observation that subcellular distribution of LC3 
was not significantly different in the CQ plus erlotinib-treated 
cells, compared with CQ-alone–treated cells, suggesting that 
CQ does not potentiate erlotinib’s cytotoxic effects by an 
effect on either the induction of autophagy, or on the rate of 
autophagic flux.
Combined Treatment with Chloroquine and  
Erlotinib Enhances the Activation of Apoptotic  
Pathways
Emerging evidence has demonstrated that erlotinib-
induced cell death is linked to the mitochondrial-mediated 
caspase-dependent signaling pathways.15 We, thus, tested 
whether disruption of autophagy with CQ could accelerate 
erlotinib-induced apoptosis in the NSCLC cells. Cells were 
treated with erlotinib or CQ alone, or with the combination 
of two agents, as described above, and after a 72-hour incuba-
tion, apoptosis were evaluated by TUNEL reaction. Erlotinib 
alone caused a significant increase in apoptosis in the sensi-
tive cell lines (H322 and H358), but not in the resistant cells 
(H460 and A549); chloroquine alone did not induce apoptosis 
in any of the cell lines (Fig. 5B). The combination of erlo-
tinib and CQ induced apoptosis in all four cell lines, and this 
was significantly greater than the apoptosis seen with erlotinib 
alone in all four cell lines. In fact, the levels of apoptosis were 
comparable in the erlotinib-sensitive and -resistant cell lines, 
suggesting that CQ completed the reversal of the resistance 
to erlotinib seen in the H460 and A549 cells to the level of 
sensitivity found in the H322 and H358 cells.
To confirm that the induction of apoptosis by CQ in 
erlotinib-treated cells was because of the inhibition of autoph-
agy, we determined the effect of knockdown of Atg-5 gene 
expression on erlotinib-induced apoptosis.23 As shown in 
Fig. 5C, transfection with Atg-5 siRNA alone did not signifi-
cantly increase apoptosis. It did, however, lead to a significant 
FIGURE 5.  Effect of CQ on erlotinib-induced autophagy and apoptosis. A, Cells were treated with 2 μM of erlotinib or 10 μM 
of CQ alone, or the combination of both agents, or with the same volume of medium containing 0.1% DMSO as a control, for 
72 hours. Immunoblot analysis of cell extracts were analyzed for LC3-I and LC3-II. The levels of LC3-II were quantified by a laser 
densitometer, normalized to β-actin, and the levels of LC3-II were then expressed relative to control cells. B, Cells were treated 
as in (A), and apoptotic cells were assessed by TUNEL reaction. Data are means ± SEM of three experiments. *Indicates signifi-
cantly different from control; **indicates significantly different from control cells and erlotinib-alone treated cells. C, Effect of 
knockdown of Atg-5 expression on erlotinib-induced apoptosis. Cells were transfected with Atg-5 or mock-siRNA for 24 hours, 
and then treated with 4 μM of erlotinib. After 72 hours, the number of apoptotic cells was determined by a TUNEL assay. Data 
are means ± SD of three independent experiments, **p < 0.01, compared with control. CQ, chloroquine; LC3, ; TUNEL, termi-
nal deoxynucleotidyl transferase dUTP nick end labeling.
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increase in apoptosis when cells were treated with erlotinib 
(p < 0.01). These results suggest that down-regulation of 
autophagy by genetic or pharmacologic means may promote 
and/or facilitate the triggering of erlotinib-induced apoptotic 
cascades.
Effect of Chloroquine on Erlotinib-
Induced Antitumor Activity In Vivo
Chloroquine and its closely related drug HCQ are 
widely used and are well tolerated in the treatment of 
malaria, rheumatoid arthritis, and lupus erythematosus. The 
possibility that they could, therefore, be used therapeutically 
as autophagy-modulating agents to potentiate the efficacy 
of erlotinib was evaluated in NSCLC tumor-bearing mice. 
For these experiments, we chose an NSCLC cell line, which 
showed little responsiveness in vitro to 2 µM of erlotinib alone 
(H460), and one which was inhibited approximately 50% by 
2 µM of erlotinib (H358) (Fig. 2). Tumor growth inhibition 
by erlotinib of these tumors in mice was consistent with that 
seen in tissue culture, with no inhibitory effect seen in H460 
tumors, and a modest antitumor effect (approximately 25%) in 
the H358 tumors (Fig. 6). As anticipated, HCQ alone had no 
effect on tumor growth in either xenograft. In contrast, HCQ 
significantly increased the antitumor activity of erlotinib in 
vivo, even against the H460 tumors, which did not respond to 
erlotinib alone. Cotreatment with HCQ increased the efficacy 
of erlotinib in the H358 tumors to approximately 90% growth 
inhibition, compared with control. That the HCQ plus erlotinib 
combination did not completely block H460 tumor growth 
suggests that autophagy induction was not the only factor 
causing resistance to erlotinib. Mechanisms of resistance likely 
include other genetic changes in the cells that are driving tumor 
growth but are not sensitive to EGFR inhibition.
All the drug treatments caused modest reductions in 
animal weight, although in no instance were these statistically 
significant (data not shown). HCQ alone caused a maximal 
10% reduction in mouse weight in both models, whereas, the 
decrease in body weight because of erlotinib averaged 15%. 
The change in body weight with the combination of HCQ + 
erlotinib (15%) was identical to that seen with erlotinib alone, 
indicating that the combined therapy did not further potentiate 
this marker of host toxicity. Furthermore, on cessation of drug 
treatment, mouse body weights rapidly recovered to that of 
control mice.
DISCUSSION
In two large randomized trials, the EGFR TKI, erlo-
tinib, demonstrated significant single-agent clinical activity, 
compared with placebo, in previously treated patients with 
NSCLC.3,4 However, the preliminary data from a recent clini-
cal trial suggested that the chemotherapy drug, docetaxel, may 
be more effective than erlotinib in improving progression-free 
survival in NSCLC patients with wild-type EGFR.24 Some 
NSCLC patients have tumors that are innately resistant to 
EGFR TKIs. However, identification of the basis for this resis-
tance and approaches to reverse it are areas of intense investi-
gation. Progress toward addressing the latter was made when 
analyses of the clinical studies showed that erlotinib produced 
significant responses and improved progression-free survival 
in NSCLC patients whose tumors had activating mutations in 
the tyrosine kinase domain of EGFR, whereas only modest 
efficacy was observed in patients with tumors with wild-type 
EGFR.5,6 The majority of EGFR mutations observed clinically 
are either a deletion of a conserved sequence in exon 19, or 
a single-point mutation in exon 21; both are activating muta-
tions that result in tumor-cell dependence on EGFR signal-
ing in a ligand-independent manner.25,38 Thus, the dependence 
of these tumors on their mutant EGFR for cell survival and 
proliferation renders them susceptible to TKIs and provides 
a seemingly rational basis for the clinical observations of 
selective sensitivity.25,38 However, only a subset (20%–30%) 
of patients have tumors with a mutant EGFR; the majority of 
NSCLC tumors have a wild-type EGFR, and thus, are rela-
tively resistant to EGFR TKIs.
Overcoming this innate resistance to erlotinib in wild-
type EGFR tumors is a major obstacle limiting the efficacy 
of the drug in NSCLC patients. More recent studies suggest 
that the association between activating EGFR mutations and 
responsiveness to EGFR TKIs is more complex than had been 
originally hypothesized.25 Confounding factors that modify 
responsiveness include changes in EGFR copy number, other 
specific EGFR mutations (e.g., T790M), overexpression of the 
FIGURE 6.  Effect of HCQ + erlotinib on tumor 
growth in vivo. Nude mice were inoculated sub-
cutaneously with 3 to 4 × 106 H460 (A) or H358 (B) 
human non–small-cell lung cancer cells. Daily oral 
drug treatment was begun 1 week later (time 0), as 
follows: vehicle control (◯); erlotinib (30 mg/kg/day) 
(▽); HCQ (162 mg/kg/day) (△); or the combination of 
HCQ + erlotinib (●). A total of 21 and 19 daily doses 
were administered to the H358- and H460-tumor 
bearing mice, respectively. Tumors were measured 
with calipers and tumor size calculated as described 
in Methods. Data are means ± SEM of five mice. 
*Indicates significantly different from vehicle control 
and HCQ alone; **indicates significantly different 
from vehicle control, HCQ alone, and erlotinib alone, 
p value was less than 0.05, by analysis of variance 
and Newman–Keul’s multiple comparison test. HCQ, 
hydroxychloroquine; SEM,standard error of mean.
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Met gene, loss of Bcl-2-like protein 11 (BIM), overexpression 
of hepatocyte growth factor (HGF), and activating mutations 
in the downstream K-Ras gene (K-Ras mutations are usually 
mutually exclusive with EGFR mutations).7,14,16,23,26,27 Thus, 
our experiments, demonstrating that chloroquine can partially 
overcome the innate resistance to erlotinib in NSCLC cells 
with both wild-type EGFR and mutated K-Ras, are highly rel-
evant clinically.
In this work, we have demonstrated that treatment with 
erlotinib, at pharmacologically achievable concentrations, 
induces autophagy in human NSCLC cells, which have 
a wild-type EGFR. Quantitative analysis revealed that 
autophagy was more pronounced in erlotinib-resistant cell 
lines (including both cells lines with mutant K-Ras) than in 
erlotinib-sensitive cells, indicating that autophagy induction 
by erlotinib may represent a cytoprotective mechanism, 
resulting in innate drug resistance. Although it has been 
reported that the EGFR TKIs, gefitinib and erlotinib, induce 
autophagy in human NSCLC cells and glioblastoma cells, 
these studies used suprapharmacologic concentrations (10–60 
μM) of the TKIs.28,29 Treatment of NSCLC patients with daily 
erlotinib (150 mg) produces steady-state plasma levels of 2 to 
4 µM. Thus, our study corroborates these earlier findings with 
a clinically achievable concentration of erlotinib (2 μM).30–32
Activation of the EGFR signaling pathway (either by 
EGF or because of mutations in the EGFR) promote anti-
apoptotic and prosurvival signals through three interrelated 
pathways: the Ras–Raf–MEK-ERK pathway; the PI3K–Akt 
pathway; and through the STAT3 and STAT5 transcription 
activators.25 Sensitivity to growth inhibition by the EGFR 
TKI, gefitinib, in response to EGFR signaling in NSCLC 
cell lines under basal growth conditions has been shown to 
be associated with dependence on Akt and ERK1/2 activation 
for survival and proliferation.14,33 Our data demonstrate that 
the ability of CQ to reverse tumor-cell resistance to erlotinib 
was not because of an increased inhibition of the activation of 
these pathways in response to EGF. Rather, we found that CQ 
induces a large increase in apoptosis in erlotinib-treated cells. 
Given the emerging appreciation of the complex functional 
relationship between apoptosis and autophagy, it is likely that 
autophagy induction in NSCLC cells with wild-type EGFR by 
erlotinib represents a stress adaptation that permits the cells to 
avoid cell death.10 CQ reverses this adaptation, and thereby, 
promotes cell death; we are currently investigating the signal-
ing pathways by which this occurs.
The striking synergistic growth inhibitory effect of 
tumors in vivo, observed when CQ and HCQ were used in 
combination with erlotinib, has important clinical implica-
tions. These drugs are widely used as antimalarials and for 
the treatment of rheumatoid arthritis, and owing to their low 
toxicity, have recently received attention as potential chemo-
sensitizers in treating tumors when used in combination with 
cytotoxic chemotherapeutic agents.23,34–36 For example, CQ 
was found to augment the antitumor activity of 5-fluorouracil 
in colon cancer cells and of oxaliplatin in hepatocellular carci-
noma cells as well as increase the therapeutic effects of TKIs, 
such as imatinib mesylate, in the treatment of chronic myeloid 
leukemia.23,35–37 In this report, we found that CQ caused a 
nearly complete abrogation of the resistance of H460 cell 
growth to erlotinib. It is important to note that this occurred 
in tissue culture with 10 µM of CQ, a concentration close to 
that seen in patients with daily dosage of 800 to 1000 mg.32,37 
Further, a recent phase I trial of erlotinib plus HCQ found that 
the combination was safe and well tolerated.32
We confirmed the therapeutic potential of the combina-
tion with in vivo tumor experiments in NSCLC xenografts. 
Interestingly, our data indicate that HCQ was effective, even in 
tumors that exhibited complete erlotinib resistance (H460), pro-
viding a rationale for testing the combination in patient popula-
tions known to be resistant to erlotinib alone. Further, there is 
no a priori reason why a chemosensitizing effect would not be 
seen clinically across the entire range of lung cancers, includ-
ing tumors that may have other mechanisms of drug resistance.
In summary, the current study demonstrates that the 
combination treatment with CQ, or other autophagy inhibi-
tors, is a novel and potentially useful clinical strategy to poten-
tiate the efficacy of EGFR-targeted cancer therapeutics. Our 
findings provide the rationale to evaluate this combination in 
clinical trials for NSCLC patients, including tumors that carry 
K-ras mutations, and those whose wild-type EGFR have been 
shown to limit the efficacy of EGFR TKIs.
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